Payment overview · 2025
General Payments
$848.78
57 reported records · 15 companies
Healthcare provider profile · identity verified
Frank Sharp, MD
Allopathic & Osteopathic Physicians|Family Medicine · LANCASTER, SC · NPI 1801880711
Verified facts
What the public records show
CMS Open Payments records show Frank Sharp, MD received $848.78 in general payments during 2025 across 57 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Kerendia, Mounjaro, Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $182.16 | 21.5% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.13 | 10.8% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.35 | 10.2% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $84.09 | 9.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $72.66 | 8.6% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $59.68 | 7.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.50 | 6.5% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $50.72 | 6.0% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.87 | 4.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $35.92 | 4.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.35 | 2.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.79 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.59 | 2.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.93 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.04 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $848.78 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $182.16 | 21 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $84.09 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $59.68 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.03 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $54.92 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.92 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $50.72 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.32 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.32 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.32 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 27 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 125 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 96 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 146 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
96 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
146 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
27 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 722 | 202 |
| Atorvastatin Calcium | Atorvastatin Calcium | 645 | 181 |
| Metoprolol Succinate | Metoprolol Succinate | 575 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 525 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 516 | 148 |
| Gabapentin | Gabapentin | 460 | 132 |
| Losartan Potassium | Losartan Potassium | 417 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 377 | 131 |
| Omeprazole | Omeprazole | 372 | 105 |
| Pravastatin Sodium | Pravastatin Sodium | 323 | 97 |
| Potassium Chloride | Potassium Chloride | 307 | 100 |
| Valsartan | Valsartan | 298 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 266 | 75 |
| Tramadol Hcl | Tramadol Hcl | 264 | 80 |
| Furosemide | Furosemide | 263 | 92 |
| Famotidine | Famotidine | 262 | 81 |
| Metformin Hcl Er | Metformin Hcl | 249 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 246 | 74 |
| Enalapril Maleate | Enalapril Maleate | 243 | 70 |
| Trazodone Hcl | Trazodone Hcl | 242 | 65 |
| Sertraline Hcl | Sertraline Hcl | 235 | 57 |
| Ezetimibe | Ezetimibe | 207 | 73 |
| Montelukast Sodium | Montelukast Sodium | 205 | 63 |
| Alendronate Sodium | Alendronate Sodium | 198 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 50 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 175 | 69 |
| Glipizide Er | Glipizide | 171 | 50 |
| Lisinopril | Lisinopril | 166 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 43 |
| Allopurinol | Allopurinol | 163 | 53 |
| Fluoxetine Hcl | Fluoxetine Hcl | 159 | 38 |
| Donepezil Hcl | Donepezil Hcl | 155 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 152 | 42 |
| Mounjaro | Tirzepatide | 146 | 20 |
| Metformin Hcl | Metformin Hcl | 145 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 44 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 126 | 34 |
| Eliquis | Apixaban | 125 | 36 |
| Carvedilol | Carvedilol | 124 | 38 |
| Tresiba Flextouch U-200 | Insulin Degludec | 124 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 29 |
| Ozempic | Semaglutide | 119 | 28 |
| Meloxicam | Meloxicam | 118 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 46 |
| Finasteride | Finasteride | 113 | 30 |
| Prednisone | Prednisone | 112 | 85 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 15 |
| Aripiprazole | Aripiprazole | 99 | 22 |
| Kerendia | Finerenone | 96 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 93 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 87 | 75 |
| Jardiance | Empagliflozin | 86 | 25 |
| Lovastatin | Lovastatin | 86 | 23 |
| Fenofibrate | Fenofibrate | 82 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 21 |
| Klor-Con M20 | Potassium Chloride | 80 | 32 |
| Benazepril Hcl | Benazepril Hcl | 74 | 17 |
| Januvia | Sitagliptin Phosphate | 73 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 72 | 19 |
| Simvastatin | Simvastatin | 72 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 69 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 17 |
| Mirtazapine | Mirtazapine | 68 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 32 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 22 |
| Meclizine Hcl | Meclizine Hcl | 62 | 31 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 62 | 46 |
| Farxiga | Dapagliflozin Propanediol | 59 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 13 |
| Levofloxacin | Levofloxacin | 56 | 49 |
| Primidone | Primidone | 55 | 17 |
| Glyxambi | Empagliflozin/Linagliptin | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 51 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 51 | 20 |
| Telmisartan | Telmisartan | 50 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 18 |
| Glipizide | Glipizide | 47 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 38 |
| Azithromycin | Azithromycin | 44 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 23 |
| Risperidone | Risperidone | 43 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Fluconazole | Fluconazole | 42 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 42 | 12 |
| Memantine Hcl | Memantine Hcl | 41 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | 14 |
| Colestipol Hcl | Colestipol Hcl | 37 | 14 |
| Naproxen | Naproxen | 37 | 17 |
| Torsemide | Torsemide | 37 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | 11 |
| Bupropion Xl | Bupropion Hcl | 35 | 12 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 23 |
| Estradiol | Estradiol | 32 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 16 |
| Novolin N Flexpen | Insulin Nph Human Isophane | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 16 |
| Lorazepam | Lorazepam | 28 | 13 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 27 | 26 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 26 |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Colchicine | Colchicine | 25 | 13 |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 21 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Haloperidol | Haloperidol | 20 | 17 |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Celecoxib | Celecoxib | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | 19 |
| Azelastine Hcl | Azelastine Hcl | 18 | 16 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 13 |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $848.78 · 57 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, GEMTESA, KRYSTEXXA, Kerendia, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, Veozah, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error